Bristol-Myers Squibb's blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 billion in sales last year.

In the face of looming revenue decline from blood cancer medication Revlimid, Indian pharma companies Natco Pharma and Dr. Reddy's Laboratories are shifting their focus to a promising new frontier ...

The brokerage noted that the expiration of the Revlimid patent in 2026 presents a considerable risk to Dr Reddy's earnings growth, as the medication accounts for approximately 40% of its FY24 EBITDA.